Another validation of RetCAD showing great performance for simultaneously screening for AMD and DR


December 20th, 2022

Another validation of RetCAD showing great performance for simultaneously screening for AMD and DR


December 20th, 2022

According to the new research by University Medical Center Hamburg-Eppendorf, RetCAD software provided very impressive results when measuring it’s sensitivity and specificity with age-related macular degeneration (AMD) and diabetic retinopathy (DR) grading.

The software proved to be as good as a human grader, showing 98.6% sensitivity and 78.3% specificity for AMD and 100.0% sensitivity and 92.3% specificity for DR.

The study was conducted with 630 patients (1245 eyes) of an ophthalmology day-care clinic. The images of the patients’ eyes were acquired by a fundus camera and graded separately by RetCAD solution and by a human-grader. The disagreements between the AI software and the human expert were then checked by a second examiner.

Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are some of the leading causes of impaired vision in the working-age population. Though these diseases can be kept under control, patients are often not aware of their conditions until it is too late. That is why regular eye screening is important. However, it requires a lot of resources to provide proper eye care. The results of the research by the University Medical Center Hamburg-Eppendorf proved that softwares like RetCAD can allow cost-effective screening where routine expert evaluation may be limited.

Read the full study here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729089/

Share This Story, Choose Your Platform!